Holen Sie sich die Stockscreener-App
2.63
1.54%
0.04
Vorhandelsmarkt:
2.73
0.10
+3.80%
Schlusskurs vom Vortag:
$2.59
Offen:
$2.66
24-Stunden-Volumen:
425.58K
Relative Volume:
0.56
Marktkapitalisierung:
$159.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-133.35M
KGV:
-1.1918
EPS:
-2.2068
Netto-Cashflow:
$-123.75M
1W Leistung:
-9.93%
1M Leistung:
-5.40%
6M Leistung:
+77.70%
1J Leistung:
+121.01%
1-Tages-Spanne:
$2.60
$2.78
1-Wochen-Bereich:
$2.52
$3.035
52-Wochen-Spanne:
$0.8551
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Firmenname
Acumen Pharmaceuticals Inc
Sektor
Branche
Telefon
617-344-4190
Adresse
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.63 | 159.31M | 0 | -133.35M | -123.75M | -2.2068 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-07-26 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-20 | Fortgesetzt | BofA Securities | Buy |
| 2023-05-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Eingeleitet | BTIG Research | Buy |
| 2022-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-07-26 | Eingeleitet | BofA Securities | Neutral |
| 2021-07-26 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-26 | Eingeleitet | Stifel | Buy |
| 2021-07-26 | Eingeleitet | UBS | Buy |
Alle ansehen
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
Acumen Pharmaceuticals Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Monday - Defense World
ABOS (Acumen Pharmaceuticals) PB Ratio : 1.74 (As of Mar. 23, 2026) - GuruFocus
If You Invested $1,000 in Acumen Pharmaceuticals, Inc. (ABOS) - Stock Titan
Aug Rallies: What hedge funds are buying Acumen Pharmaceuticals IncWeekly Trend Report & Trade Opportunity Analysis - baoquankhu1.vn
Wall Street Zen Downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) to Sell - MarketBeat
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Acumen Pharmaceuticals Inc - GuruFocus
Dip Buying: How does Acumen Pharmaceuticals Inc perform in inflationary periods2026 Intraday Action & Stepwise Trade Signal Implementation - baoquankhu1.vn
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 - The Manila Times
Alzheimer's drug developer Acumen sets March 26 results webcast - Stock Titan
Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at Conference - MarketBeat
RA Capital entities boost Acumen (NASDAQ: ABOS) stake with 6.1M-share grant - Stock Titan
Acumen Pharmaceuticals at Stifel Forum: Strategic Insights on Alzheimer’s Drug - Investing.com Canada
ABOS: Phase II Alzheimer's trial for sabirnetug targets late 2026 data, with EBD clinical entry by 2027 - TradingView
Acumen Pharmaceuticals, Inc. unveils novel antibodies targeting amyloid beta oligomers at ADPD2026 - Traders Union
Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Price Expected to Rise, BTIG Research Analyst Says - Defense World
Acumen Pharma Presents Brain Delivery Studies at Alzheimer’s and Parkinson’s Diseases Conference 2026 - Yahoo Finance
RA Capital boosts Acumen (ABOS) ownership to 29.5% after $20M PIPE buy - Stock Titan
Acumen Unveils Enhanced Brain Delivery Technology and Latest Alzheimer's Research Findings at International AD/PD Conference - citybiz
Private placement at Acumen to advance EBD program - BioWorld MedTech
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $8.00 - MarketBeat
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026 - Bitget
Mouse study boosts brain delivery of Acumen’s Alzheimer’s antibody - Stock Titan
Acumen Raises Capital to Advance Enhanced Brain Delivery - The Globe and Mail
Dow Update: Whats Acumen Pharmaceuticals Incs historical return2026 Short Interest & Entry and Exit Point Strategies - baoquankhu1.vn
Institution Moves: Is Acumen Pharmaceuticals Inc a strong candidate for buy and hold2026 Macro Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Acumen Pharmaceuticals Raises $35.75 Million to Advance Enhanced Brain Delivery Alzheimer’s Therapy with Strong Preclinical Results 1 - Minichart
Acumen secures funding to advance enhanced brain delivery program - MSN
Acumen Pharmaceuticals, Inc. announced that it has received $35.749992 million in funding from RA Capital Management, L.P., ADAR1 Capital Management, LLC, Sands Capital Alternatives, LLC and other investors - marketscreener.com
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio - Bitget
Acumen Pharmaceuticals Raises $35.75 Million in Private Placement to Fund EBD Program - TradingView
Acumen Pharmaceuticals (NASDAQ: ABOS) secures $35.75M to advance EBD Alzheimer’s program - Stock Titan
Acumen Pharmaceuticals announces $35.75 million Private Placement to advance potential best-in-class molecules from amyloid beta oligomer-selective enhanced brain delivery portfolio - marketscreener.com
Acumen Pharmaceuticals Announces $35.75 Million Private Placement To Advance Potential Best-In-Class Molecules From Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio - TradingView
ABOS SEC FilingsAcumen Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
ABOS Forecast, Price Target & Analyst Ratings | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
Team members drive company mission, Acumen Pharmaceuticals, Inc. asserts - Traders Union
Acumen Pharma chief legal officer sells $6813 in stock By Investing.com - Investing.com Canada
Acumen (NASDAQ: ABOS) legal chief sells 2,090 shares after option exercise - Stock Titan
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Bitget
Alzheimer's therapeutics developer joins Stifel 2026 virtual CNS forum - Stock Titan
Stock Market Recap: What is the earnings history of Acumen Pharmaceuticals Inc2026 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
Highs Report: Is Acumen Pharmaceuticals Inc a turnaround story2025 Fundamental Recap & Expert Verified Movement Alerts - baoquankhu1.vn
Aug Spikes: What is the earnings history of Acumen Pharmaceuticals Inc2025 Price Action Summary & Real-Time Volume Analysis - baoquankhu1.vn
Acumen Pharmaceuticals (NASDAQ: ABOS) files Form 144 for insider sale - Stock Titan
Acumen Pharmaceuticals to Highlight New Alzheimer’s Research Progress at AD/PD™ 2026 - citybiz
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.80 Consensus Price Target from Analysts - Defense World
Acumen Pharma chief legal officer Meisner sells $28k in shares - Investing.com Australia
Acumen (NASDAQ: ABOS) CLO exercises options and sells 9,406 shares - Stock Titan
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026 - mx.advfn.com
Acumen Pharmaceuticals to showcase advances in Alzheimer's treatment at international conference on Alzheimer's and Parkinson's diseases 2026 - marketscreener.com
Finanzdaten der Acumen Pharmaceuticals Inc-Aktie (ABOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):